Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Significant Decline in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 2,050,094 shares, a decrease of 15.3% from the January 29th total of 2,419,408 shares. Currently, 5.5% of the company’s shares are short sold. Based on an average trading volume of 329,823 shares, the days-to-cover ratio is presently 6.2 days. Based on an average trading volume of 329,823 shares, the days-to-cover ratio is presently 6.2 days. Currently, 5.5% of the company’s shares are short sold.

Insider Buying and Selling

In other Werewolf Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $0.97, for a total value of $80,733.10. Following the transaction, the insider directly owned 4,784,111 shares of the company’s stock, valued at $4,640,587.67. The trade was a 1.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ansbert Gadicke sold 83,230 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $0.97, for a total value of $80,733.10. Following the completion of the sale, the insider owned 4,784,111 shares of the company’s stock, valued at $4,640,587.67. The trade was a 1.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,128,294 shares of company stock worth $864,401 in the last ninety days. 23.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth approximately $409,000. Finally, Citadel Advisors LLC bought a new position in Werewolf Therapeutics during the 3rd quarter valued at approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Wedbush downgraded Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a report on Friday, December 19th. HC Wainwright lowered their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, December 19th. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Stock Up 4.7%

Shares of HOWL stock traded up $0.03 during midday trading on Wednesday, reaching $0.61. 156,932 shares of the stock were exchanged, compared to its average volume of 466,591. Werewolf Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.38. The firm has a market cap of $29.73 million, a PE ratio of -0.38 and a beta of 0.78. The company’s 50 day moving average is $0.64 and its two-hundred day moving average is $1.10. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.